OVO Biomanufacturing, a spin-out from the University of Warwick and Coventry University, is developing digital solutions to improve the efficiency of viral vaccine and gene therapy manufacture. OVO’s technology allows manufacturers of both established and novel viral vaccines and gene therapies to maximise the production of the target virus used to produce each therapy. The technology can be applied to any virus that is grown to produce a vaccine or therapy. Improving the efficiency of manufacture can improve yield, cut lead times and costs and maximise distribution, which is essential for current and future pandemics.
OVO Biomanufacturing are the world leading experts in providing technical solutions to solve the effects of defective interfering particles for viral vaccine manufacturers. OVO’s novel technology platform offers multi-fold yield improvements by reducing the generation and effect of these particles during all stages of vaccine manufacture. OVO’s platform can be used to manage defective interfering particles for both established and developing live attenuated and inactivated viral vaccines. Our platform can be implemented without significantly altering production processes or regulatory compliance.
Our technology can be applied to both inactivated and live attenuated vaccines. This covers over 95% of the $5 billion flu vaccine market. With the current COVID-19 crisis it is essential that vaccine manufacturers are able to maximise manufacturing yield. Our platform can be applied to live attenuated, inactivated and some live viral vector vaccines.
In December 2020, Ovo Biomanufacturing announced the completion of a funding round. The funding came from the GM&C Life Sciences Fund, managed by Catapult Ventures.